Aktis Oncology valued at $1.4B, eyes 2027 trial data to boost radiopharmaceutical pipeline.

Aktis Oncology, a clinical-stage radiopharmaceutical company, closed at $25.00 on August 18, 2026, with a market cap of $1.4 billion and $517.3 million in cash, supporting operations into 2029. Its lead candidate targets Nectin-4 with trial data expected in early 2027, while a second program targets B7-H3 in several cancers. The company holds exclusive global rights to its pipeline, with a collaboration agreement with Lilly covering other targets. Potential acquirers include Novartis, Eli Lilly, and Bristol Myers Squibb, with analysts bullish ahead of key trial readouts and facility developments in 2026-2027.